Article

RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy

2024-03-21

Abstract excerpt

<title>Abstract</title> <p>RIT1 is a RAS-family GTPase that is mutated in 2.4% and amplified in up to 14% of lung adenocarcinoma patients. Yet, the oncogenic potential of RIT1 in the lungs is not completely understood. Many patients with RIT1 alterations are considered ‘oncogene-negative’, hence they are not eligible for any targeted therapy in the clinic. The role of RIT1 in cancer has been historically understu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bf24fd1b-e500-54e0-a1b6-9a8ab82ffb6d
DOI: 10.21203/rs.3.rs-4067022/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapyDOI 10.21203/rs.3.rs-4067022/v1Read

RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy.Semantic proximity Read

Oncogenic RIT1 mutations in lung adenocarcinoma.Semantic proximity Read

RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma.Semantic proximity Read

Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non-Small Cell Lung Cancer.Semantic proximity Read

Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer stateSemantic proximity Read

Oncogenic RIT1 mutations confer ferroptosis vulnerability in lung adenocarcinoma.Semantic proximity Read

The molecular functions of RIT1 and its contribution to human disease.Semantic proximity Read

An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancerSemantic proximity Read

Mapping the unique and shared functions of oncogenic KRAS and RIT1 with proteome and transcriptome profilingSemantic proximity Read

Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.Semantic proximity Read

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistanceSemantic proximity Read

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.Semantic proximity Read